Compare · LITS vs NVO
LITS vs NVO
Side-by-side comparison of Lite Strategy Inc. (LITS) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LITS and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $213.34B, about 6321.8x LITS ($33.7M).
- Over the past year, LITS is down 85.2% and NVO is down 31.0% - NVO leads by 54.2 points.
- NVO has hit the wire 5 times in the past 4 weeks while LITS has been quiet.
- NVO has more recent analyst coverage (25 ratings vs 0 for LITS).
- Company
- Lite Strategy Inc.
- Novo Nordisk A/S
- Price
- $0.98-2.97%
- $48.78+1.22%
- Market cap
- $33.7M
- $213.34B
- 1M return
- +13.27%
- +2.89%
- 1Y return
- -85.20%
- -31.04%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2003
- News (4w)
- 0
- 5
- Recent ratings
- 0
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest LITS
- Director Flynn James P bought $21,388 worth of shares (25,000 units at $0.86), increasing direct ownership by 25% to 125,000 units (SEC Form 4)
- Lite Strategy to Attend Panel at Litecoin Foundation Summit in Amsterdam
- Lite Strategy Leads Strategic Investment in LitVM
- Lite Strategy Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form 10-Q filed by Lite Strategy Inc.
- Lite Strategy Reports Fiscal 2026 Third Quarter Results
- Lite Strategy Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Lite Strategy Reports Fiscal 2026 Second Quarter Results
- SEC Form 10-Q filed by Lite Strategy Inc.
- SEC Form 4 filed by CEO, CFO and Secretary File Justin J.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S